Literature DB >> 26470961

Ocular infections caused by Candida species: Type of species, in vitro susceptibility and treatment outcome.

S R Motukupally, V R Nanapur, K N Chathoth, S I Murthy, R R Pappuru, A Mallick, S Sharma1.   

Abstract

PURPOSE: To report clinical and microbiological profile of patients with ocular candidiasis.
MATERIALS AND METHODS: Patients with ocular candidiasis were retrospectively identified from microbiology records. Significant isolates of Candida species were identified by Vitek 2 compact system. Minimum inhibitory concentration (MIC) of antifungal agents such as amphotericin B, itraconazole, voriconazole, fluconazole and caspofungin was determined by E test and of natamycin by microbroth dilution assay. Data on treatment and outcome were collected from medical records.
RESULTS: A total of 42 isolates of Candida were isolated from patients with keratitis-29, endophthalmitis-12 and orbital cellulitis-1. The most common species isolated was Candida albicans (12-keratitis, 4-endophthalmitis, 1-orbital cellulitis). All except one isolate were susceptible to amphotericin B. MIC of caspofungin was in the susceptible range in 28 (96.5%) corneal isolates while 12 out of 29 (41.3%) corneal isolates were sensitive to fluconazole. Resistance to voriconazole was seen in four corneal isolates. All isolates were susceptible to natamycin and all except two isolates were resistant or susceptible dose-dependent to itraconazole. Outcome of healed ulcer was achieved in 12/18 (66.6%) patients treated medically, while surgical intervention was required in 11 patients. Among the isolates from endophthalmitis patients, 11/12 were susceptible to amphotericin B, 6/12 to voriconazole and all to natamycin. Ten out of 11 patients (one patient required evisceration) with endophthalmitis were given intravitreal amphotericin B injection with variable outcome.
CONCLUSIONS: Ocular candidiasis needs early and specific treatment for optimal results. Candida species continue to be susceptible to most commonly available antifungals including amphotericin B, voriconazole and natamycin.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26470961     DOI: 10.4103/0255-0857.167331

Source DB:  PubMed          Journal:  Indian J Med Microbiol        ISSN: 0255-0857            Impact factor:   0.985


  6 in total

1.  Dual Drug Loaded Lipid Nanocarrier Formulations for Topical Ocular Applications.

Authors:  Ahmed Adel Ali Youssef; Narendar Dudhipala; Soumyajit Majumdar
Journal:  Int J Nanomedicine       Date:  2022-05-18

2.  Candida dubliniensis: A novel cause of fungal keratitis.

Authors:  Tyler D Oostra; Lynn R Schoenfield; Thomas F Mauger
Journal:  IDCases       Date:  2018-08-14

3.  Bilateral Candida keratitis in an HIV patient with asymptomatic genitourinary candidiasis in Uganda.

Authors:  Simon Arunga; Teddy Kwaga; Astrid Leck; Victor H Hu; Matthew J Burton
Journal:  Med Mycol Case Rep       Date:  2018-07-17

4.  Understanding the science of fungal endophthalmitis - AIOS 2021 Sengamedu Srinivas Badrinath Endowment Lecture.

Authors:  Taraprasad Das; Joveeta Joseph; Saumya Jakati; Savitri Sharma; Thirumurthy Velpandian; Srikant K Padhy; Vipin A Das; Sisinthy Shivaji; Sameera Nayak; Umesh C Behera; Dilip K Mishra; Jaishree Gandhi; Vivek P Dave; Avinash Pathengay
Journal:  Indian J Ophthalmol       Date:  2022-03       Impact factor: 2.969

5.  Brown Heroin-Associated Candida albicans Ventriculitis and Endophthalmitis Treated with Voriconazole.

Authors:  Nora Elfiky; Kelly Baldwin
Journal:  Case Rep Neurol       Date:  2016-07-08

6.  Alterations in the gut bacterial microbiome in fungal Keratitis patients.

Authors:  Sama Kalyana Chakravarthy; Rajagopalaboopathi Jayasudha; Konduri Ranjith; Anirban Dutta; Nishal Kumar Pinna; Sharmila S Mande; Savitri Sharma; Prashant Garg; Somasheila I Murthy; Sisinthy Shivaji
Journal:  PLoS One       Date:  2018-06-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.